Designed to be the first non-hormonal oral therapeutic for pattern hair loss in women and men
VDPHL01 has the potential to be the first extended-release oral minoxidil designed specifically for women and men with pattern hair loss.
Pattern hair loss is the largest aesthetics condition worldwide, yet there have been no new prescription therapies in nearly 30 years, and no oral prescription therapies approved by the U.S. Food and Drug Administration (FDA) for women.
Not an actual patient
Veradermics utilized a proprietary extended-release technology to create VDPHL01, an oral tablet designed to extend exposure of minoxidil to hair follicles over time.
This release profile is designed to extend exposure of minoxidil to hair follicles over time and is being evaluated in ongoing clinical trials.
clinical trials
Phase 2 and 3 trials for males and females are underway
This work represents one of the most comprehensive clinical development programs ever undertaken for PHL.
Phase 2 Trials
The open-label, multi-dose Phase 2 trial is evaluating the safety and efficacy of VDPHL01 in men and women with mild to moderate pattern hair loss for primary endpoints of target area hair count and patient reported outcomes on the treatment’s effectiveness. Enrollment began first with males, and treatment is currently ongoing in both male and female study participants for Phase 2.
Veradermics has reported positive preliminary results from the Phase 2 trial. For details, see the full press release in our Investors section.
